Skip to main content
. Author manuscript; available in PMC: 2021 Dec 1.
Published in final edited form as: Hepatology. 2020 Nov 13;72(6):2165–2181. doi: 10.1002/hep.31239

Figure 7: N-Acetyl-L-(+)-cysteine (NAC) can partially ameliorate liver injury in SCD mice.

Figure 7:

(A) Schematic diagram of NAC administration scheme. (B) Western Blot for NF-κB(P65) confirms significant upregulation in the liver of SCD mice which was reduced upon NAC treatment. qRT-PCR analysis reveals the expression level of NF-κB and its target genes in control and SCD mice with or without NAC treatment. (C) Blood serum analysis showing ALP,ALT and AST level in control and SCD mice with or without NAC treatment after 4,8,10 and 12 weeks of treatment. Serum analysis of direct and total bilirubin levels in control and SCD mice with or without NAC treatment after 4,8,10 and 12 weeks of treatment. (D) Immunohistochemical characterization of SCD mice with or without NAC treatment using H&E, sirius red and αSMA staining. (E) qLIM image of control and SCD liver. Dotted circle indicates the loss of flow of blood across the liver sinusoids in SCd liverwhich was ameliorated after NAC treatment. Quantification of the total area of liver with loss of blood flow in SCD and SCD+NAC mice. (F) qRT-PCR analysis reveals the expression level of FXR and its target genes in control, SCD and SCD mice with NAC treatment. * denotes p>0.05.# denotes p>0.1.